Emerging Strategies for Neuroprotection and Neuroregeneration in Multiple Sclerosis
Existing disease-modifying therapies (DMTs) have been generally successful in limiting the damaging effects of relapsing forms of multiple sclerosis (MS) in many patients. But there is still a significant need for new approaches that can halt neurologic damage altogether, or even regenerate nerve tissue in patients who have sustained irreversible damage. MS remains a heterogeneous disease with varying response to therapy among patients with all forms of the disease. And, despite suppression from DMT use, MS does progress over time in most patients.

This activity is a webcast of a roundtable based on presentations at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the 15th Conference of Rehabilitation in Multiple Sclerosis (RIMS) held in October 2010.

On completion, participants should be able to:
• Summarize the current scientific knowledge of neurodegenerative mechanisms in MS;
• Explain the mechanisms by which newer, experimental agents for MS may confer neuroprotection;
• Describe current clinical trial data relating to promising approaches for neuroprotection in MS;
• Discuss current findings in neuroprotection with patients in a way that offers encouragement while maintaining scientific integrity;
• Evaluate current research to determine which areas are promising and which may be considered preliminary or misleading.

» Go to this activity

Multiple Sclerosis 2010: The Current State of Treatment
Multiple sclerosis is a chronic autoimmune disorder that is estimated to affect about 400,000 individuals in the United States. Results from published immunopathological studies indicate that the irreversible axonal damage that causes disability begins very early in the course of the disease. Treating patients early appears to have a significant impact on relapse frequency versus initiating treatment later in the disease course.

This video-based activity focuses on evidence-based data supporting the initiation of early treatment with disease-modifying treatments in patients with MS. Also covered in this moderated expert panel discussion are recent data on the effects of disease-modifying treatments on cognition and neuroprotection in patients with MS and the efficacy and safety of current and emerging therapies as well as strategies for treatment of patients with MS.

Upon completion, participants will be able to:
• Discuss evidence-based data supporting the initiation of early treatment with disease-modifying treatments in patients with MS;
• Discuss methods for overcoming challenges associated with effective treatments for MS;
• Review evidence-based data discussing the effects of disease-modifying treatments on cognition and neuroprotection in patients with MS;
• Review recent data discussing the efficacy of current and emerging therapies as well as their use in treatment strategies for MS;
• Discuss the clinical significance of safety profiles of existing and emerging therapies for MS.

» Go to this activity

You are subscribed to ModernMedicine.com. To unsubscribe, click here

To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.